It has been two months since the sharp pullback in A-shares on April 7. As of June 9, over 60% of active equity funds have successfully “climbed the pit”, and the net value of the fund has returned to the level of two months ago. Among them, pharmaceutical-themed funds that focus on innovative drugs and other sectors are making great strides, attacking the “champion” of semi-annual active equity funds. At the beginning of June, the artificial intelligence industry chain, represented by computing power, began to gain strength. The net worth of many funds heavily harboring AI targets soared, and the retracement of the past two months has just been smoothed out. Approaching the mid-year stage, the change in market style has sparked a buzz in the market. Some industry insiders suggested that the innovative drugs and new consumer sectors have recently shown signs of adjustment. The internal rotation within the market is relatively sufficient, and we should be wary of short-term adjustments under the capital stock game. Beginning in mid-June, dividend assets will enter the centralized dividend time window, and there may be pressure to cash out after the dividend date. If capital flows out of defensive assets, or if it is financially beneficial to other styles of assets, the theoretical offensive direction of technology will greatly benefit, and low-level types of technology with catalytic factors for the industry may have opportunities for excessive earnings.

It has been two months since the sharp pullback in A-shares on April 7. As of June 9, over 60% of active equity funds have successfully “climbed the pit”, and the net value of the fund has returned to the level of two months ago. Among them, pharmaceutical-themed funds that focus on innovative drugs and other sectors are making great strides, attacking the “champion” of semi-annual active equity funds. At the beginning of June, the artificial intelligence industry chain, represented by computing power, began to gain strength. The net worth of many funds heavily harboring AI targets soared, and the retracement of the past two months has just been smoothed out. Approaching the mid-year stage, the change in market style has sparked a buzz in the market. Some industry insiders suggested that the innovative drugs and new consumer sectors have recently shown signs of adjustment. The internal rotation within the market is relatively sufficient, and we should be wary of short-term adjustments under the capital stock game. Beginning in mid-June, dividend assets will enter the centralized dividend time window, and there may be pressure to cash out after the dividend date. If capital flows out of defensive assets, or if it is financially beneficial to other styles of assets, the theoretical offensive direction of technology will greatly benefit, and low-level types of technology with catalytic factors for the industry may have opportunities for excessive earnings.